SSII SS Innovations International, Inc. NASDAQ · United States

SS Innovations International (SSII) news SSII convertible notes news

Debt Financing · Oct 9, 2026

SS Innovations issues $21,025,000.00 secured convertible note

Growth Capital Partners, LLC is the lender. The note carries 8.75% interest, matures 36 months after the purchase price date and converts at 95% of a market price.

Latest SS Innovations International news

We have not published a story on SS Innovations International yet. When there is news, it will appear here.

SS Innovations International annual financials

Line	FY2025	FY2024
Revenue	$42.5 million	$20.6 million
Research and development	$3.7 million	$2.5 million
Net income (loss)	-$12.1 million	-$19.2 million
Cash from operations	-$18.5 million	-$9.5 million
Cash and equivalents	$3.2 million	$466,500

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $13.6 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about SS Innovations International

Has SS Innovations International sold convertible notes?

Our latest story on this, dated Oct 9, 2026: "SS Innovations issues $21,025,000.00 secured convertible note". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of SS Innovations International?

SS Innovations International, Inc. trades under the ticker SSII on NASDAQ.

Where is SS Innovations International listed?

SS Innovations International, Inc. is listed on NASDAQ.

Which country or territory is SS Innovations International listed under?

Our directory records SS Innovations International, Inc. under United States.

Does aibio.space cover SS Innovations International?

aibio.space lists SS Innovations International, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What was SS Innovations International's revenue last year?

$42.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is SS Innovations International profitable?

SS Innovations International, Inc. reported a net loss of $12.1 million for the fiscal year ended Dec 31, 2025, and used $18.5 million of cash in operations, per its annual report to the SEC.

How much does SS Innovations International spend on research and development?

$3.7 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does SS Innovations International have?

$13.6 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest SS Innovations International (SSII) stock news?

Our latest story on SS Innovations International, dated Oct 9, 2026: "SS Innovations issues $21,025,000.00 secured convertible note". Growth Capital Partners, LLC is the lender. The note carries 8.75% interest, matures 36 months after the purchase price date and converts at 95% of a market price. Source.

How can I follow SS Innovations International (SSII) news?

Press Follow on this page to add SS Innovations International to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming SS Innovations International so far, in Debt Financing.

Investor discussion: SS Innovations International

Members talk about SS Innovations International (SSII). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at SS Innovations International, newest first. Each line links the filing it comes from.

Oct 9, 2026Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Aug 13, 2026Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Jun 18, 2026Financings
Reported a financing. SEC Form 424B5. Source
May 20, 2026Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:SSII on TradingView.

Listing details

SS Innovations International, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SSII, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company: SS Innovations International, Inc.
Ticker: SSII
Listing: NASDAQ
Country or territory: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction